Mereo BioPharma Group PLC ADR - Asset Resilience Ratio
Mereo BioPharma Group PLC ADR (MREO) has an Asset Resilience Ratio of 66.01% as of December 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does Mereo BioPharma Group PLC ADR carry for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2022)
This chart shows how Mereo BioPharma Group PLC ADR's Asset Resilience Ratio has changed over time. See Mereo BioPharma Group PLC ADR (MREO) shareholders funds for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Mereo BioPharma Group PLC ADR's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see MREO company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $51.10 Million | 66.01% |
| Total Liquid Assets | $51.10 Million | 66.01% |
Asset Resilience Insights
- Very High Liquidity: Mereo BioPharma Group PLC ADR maintains exceptional liquid asset reserves at 66.01% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Mereo BioPharma Group PLC ADR Industry Peers by Asset Resilience Ratio
Compare Mereo BioPharma Group PLC ADR's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Mereo BioPharma Group PLC ADR (2015–2022)
The table below shows the annual Asset Resilience Ratio data for Mereo BioPharma Group PLC ADR.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 66.01% | $51.10 Million | $77.41 Million | +65.56pp |
| 2021-12-31 | 0.45% | $769.47K | $170.96 Million | -0.42pp |
| 2020-12-31 | 0.87% | $748.03K | $86.08 Million | +0.24pp |
| 2019-12-31 | 0.63% | $720.63K | $114.52 Million | -3.09pp |
| 2018-12-31 | 3.72% | $2.50 Million | $67.28 Million | +1.12pp |
| 2017-12-31 | 2.60% | $2.50 Million | $96.34 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $86.76 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $107.30 Million | -- |
About Mereo BioPharma Group PLC ADR
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navi… Read more